Add BrightSurf on Google Email

The Society of Vertebrate Paleontology sues the Trump Administration for shrinking Bears Ears National Monument

The Society of Vertebrate Paleontology joins co-plaintiffs in suing the Trump Administration for shrinking Bears Ears National Monument, which lost nearly 3 million acres of national monument protections. The organization asserts that the President's proclamation reducing Bears Ears was illegal and violates the Antiquities Act.

Hormone health climbs the policy agenda as endocrine leaders meet for European Society of Endocrinology’s first Summit of the Presidents

The summit brought together endocrine leaders to identify opportunities to work closely together on increasing the visibility of endocrine health in policy decisions. Early findings from a workforce survey revealed challenges including long patient waiting times and retention concerns among early-career clinicians.

ISSCR develops roadmap to accelerate pluripotent stem cell-derived therapies to patients

The ISSCR has released a comprehensive roadmap for developing pluripotent stem cell-derived therapies, outlining critical scientific, manufacturing, and regulatory guidance. The Best Practices document provides a risk-based, end-to-end development strategy to support informed decision-making across seven essential areas.

SourceInternational Society for Stem Cell Research·JournalStem Cell Reports·DateJan 22, 2026

Experts urge evidence-based regulations of 7-OH, not restriction, as new science emerges showing safe use

A combination of data from the FDA and independent studies confirms 7-OH's strong real-world safety profile, with no confirmed deaths reported despite over half a billion estimated doses consumed nationwide. The analysis also found that 7-OH has a significantly lower risk profile than many other natural compounds currently on the market.

SourceRunSwitch Public Relations·TypeData/statistical analysis·DateJul 8, 2025

Medtech innovator GeniPhys receives FDA clearance for first-in-kind self-assembling collagen scaffold for applications in advanced wound care

GeniPhys has received FDA clearance for its self-assembling collagen scaffold, Collymer Self-Assembling Scaffold (SAS), which supports cellular infiltration and vascularization. The technology is indicated for various wound types and anchors a growing intellectual property portfolio with nearly 20 issued or pending patents.

IVI kicks off first ‘Introductory Course for Biologics Development and Manufacturing’ to train 117 people from 25 LMICs on July 18

The International Vaccine Institute (IVI) has launched a two-week training course for biologics development and manufacturing, targeting low- and middle-income countries. The program aims to enhance local production of vaccines and biologics in LMICs to address vaccine inequity and global pandemic preparedness.

EU, US regulators apply similar mindset when advising live biotherapeutic product developer

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have applied a similar mindset when advising live biotherapeutic product developer YSOPIA Bioscience. This collaboration has provided valuable regulatory feedback for the company's clinical development efforts. The review highlights the need for harmonize...

SourcePharmabiotic Research Institute (PRI)·JournalFrontiers in Medicine·TypeCase study·DateSep 9, 2021

FDA considers new rules to speed up confirmatory trials of drugs granted accelerated approval

The FDA is considering new rules to speed up confirmatory trials of drugs granted accelerated approval, following a review that found six indications remained on the market without confirmation. The median time between accelerated and regular approval was 3.9 years, with some drugs remaining on the market for over 10 years.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 25, 2011

Making individual health insurance market work

The article argues that guaranteed renewability pools risk and protects consumers from price increases without resorting to heavy regulation of the market or reduced consumer choice. It also prevents adverse selection by preventing those who know they are likely to get sick from buying more generous coverage.

SourceHealth Affairs·JournalHealth Affairs·DateAug 28, 2002